141 related articles for article (PubMed ID: 37708442)
1. Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias.
Gomez-Lumbreras A; Mercadal Vilchez S; Villa-Zapata L; Malone DC; Couriel DR
Leuk Lymphoma; 2023 Dec; 64(13):2071-2080. PubMed ID: 37708442
[TBL] [Abstract][Full Text] [Related]
2. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
Fusaroli M; Isgrò V; Cutroneo PM; Ferrajolo C; Cirillo V; Del Bufalo F; Raschi E; Poluzzi E; Trifirò G
Drug Saf; 2022 Aug; 45(8):891-908. PubMed ID: 35829913
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
Ren X; Zhang G; Li G; Wang Y
BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
[TBL] [Abstract][Full Text] [Related]
4. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Wesson W; Ahmed N; Rashid A; Tabak C; Logan E; Marchena-Burgos J; Nelson M; Davis JA; McGann M; Shune L; Hoffmann M; Abdallah AO; Hashmi H
Eur J Haematol; 2024 Apr; 112(4):538-546. PubMed ID: 38044594
[TBL] [Abstract][Full Text] [Related]
6. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
7. Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective.
Si X; Gu T; Liu L; Huang Y; Han Y; Qian P; Huang H
Cancer Lett; 2022 Dec; 550():215920. PubMed ID: 36122628
[TBL] [Abstract][Full Text] [Related]
8. Ocular toxicities in chimeric antigen receptor T-cell therapy: a real-world study leveraging FAERS database.
Zhao N; Hu F; Zhai Y; Ye X; Ruan Y; Liu Z; Wang Z; Shen W; Yuan L
Immunotherapy; 2024 Feb; 16(3):161-172. PubMed ID: 38126138
[TBL] [Abstract][Full Text] [Related]
9. Updated insights on cardiac risks of CD19-directed chimeric antigen receptor T-cell therapy: a pharmacovigilance study.
Zhai Y; Hu F; Zhu B; Xu J; Guo X; Shi W; Zhou X; Zheng Y; Xu X; Ye X; He J; Xu F
Immunotherapy; 2023 Apr; 15(6):443-456. PubMed ID: 36951157
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis.
Guha A; Addison D; Jain P; Gutierrez JM; Ghosh A; Roddie C; de Lima M; Al-Kindi S; Oliveira GH
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2211-2216. PubMed ID: 32966880
[TBL] [Abstract][Full Text] [Related]
11. Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel.
Dores GM; Jason C; Niu MT; Perez-Vilar S
Am J Hematol; 2021 Sep; 96(9):1087-1100. PubMed ID: 34050534
[TBL] [Abstract][Full Text] [Related]
12. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
Goldman A; Maor E; Bomze D; Liu JE; Herrmann J; Fein J; Steingart RM; Mahmood SS; Schaffer WL; Perales MA; Shouval R
J Am Coll Cardiol; 2021 Nov; 78(18):1800-1813. PubMed ID: 34711339
[TBL] [Abstract][Full Text] [Related]
13. Ocular adverse events following CAR-T cell therapy: A pharmacovigilance study and systematic review.
Frey C; Cherniawsky H; Etminan M
Eur J Haematol; 2024 Jul; 113(1):66-71. PubMed ID: 38549191
[TBL] [Abstract][Full Text] [Related]
14. Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy.
Iqbal M; Bansal R; Yassine F; Gandhi S; Rosenthal A; Moustafa MA; Li Z; Craver EC; Mohty R; Murthy H; Ayala E; Tun H; Munoz J; Castro J; Lin Y; Kharfan-Dabaja MA
Transplant Cell Ther; 2022 Oct; 28(10):668.e1-668.e6. PubMed ID: 35842124
[TBL] [Abstract][Full Text] [Related]
15. Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms.
Brudno JN; Natrakul D; Lam N; Dulau-Florea A; Yuan CM; Kochenderfer JN
Leuk Lymphoma; 2022 Aug; 63(8):1849-1860. PubMed ID: 35389319
[TBL] [Abstract][Full Text] [Related]
16. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
Dolladille C; Ederhy S; Ezine E; Choquet S; Nguyen LS; Alexandre J; Moslehi JJ; Dechartres A; Salem JE
Am J Hematol; 2021 Sep; 96(9):1101-1111. PubMed ID: 34057232
[TBL] [Abstract][Full Text] [Related]
19. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.
Xia Y; Zhang J; Li J; Zhang L; Li J; Fan L; Chen L
Ann Med; 2022 Dec; 54(1):2951-2965. PubMed ID: 36382675
[TBL] [Abstract][Full Text] [Related]
20. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]